Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trialKayvon Modjarrad, Emmanuel Feroldi, Jack Hutter et al.|The Lancet Infectious Diseases|2024Cited by 8